⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TEVA News
Teva Pharmaceutical Industries Limited American Depositary Shares
Riassunto: Teva e Polpharma Biologics annunciano un accordo di licenza globale relativo a un candidato biosimilare per Ocrevus® (ocrelizumab) nella sclerosi multipla
businesswire.com
TEVA
Resumen: Teva y Polpharma Biologics anuncian un acuerdo de licencia internacional para un candidato a biosimilar de Ocrevus® (ocrelizumab) para la esclerosis múltiple
businesswire.com
TEVA
Samenvatting: Teva en Polpharma Biologics kondigen een globale licentieovereenkomst aan voor een biosimilair kandidaatgeneesmiddel voor Ocrevus® (ocrelizumab) ter behandeling van multiple sclerose
businesswire.com
TEVA
Teva et Polpharma Biologics annoncent la signature d’un accord de licence mondial portant sur un candidat biosimilaire à l’Ocrevus® (ocrelizumab) destiné au traitement de la sclérose en plaques
businesswire.com
TEVA
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis
businesswire.com
TEVA
EMBC Alert: Embecta Securities Class Action After Stock Dropped 57% is Pending - August 17 Legal Deadline is Imminent
accessnewswire.com
EMBC
TSLA
TEVA
$AVAV Class Action: AeroVironment Faces Securities Fraud Allegations after Stock Dropped 17% on SCAR Contract Cancellation
accessnewswire.com
AVAV
TSLA
TEVA
AVAV Investment Loss: AeroVironment Investors that Lost Money after SCAR Contract Cancellation are Notified to Contact BFA Law about the Filed Securities Fraud Class Action
globenewswire.com
AVAV
TSLA
TEVA
Drug-Delivery Technology Market Report 2026
globenewswire.com
MRK
ABBV
SNY
AZN
NVS
GSK
TEVA
REGN
VRTX
ALKS
HALO
Investor Alert: ZoomInfo Stock Dropped 33% Amid AI Integration Issues - Securities Fraud Class Action to Recover Losses Filed
accessnewswire.com
GTM
TSLA
TEVA